In the News

  • || Anchors aweigh: Catamaran Bio sets sail with $42M to develop allogeneic CAR-NK cell therapies

    BIOWORLD || Catamaran Bio Inc., a Boston-based startup that has raised $42 million in seed and series A financing, is considering the administration ofengineered natural killer cells in walk-in clinics.

      View Full Article
  • || SV health-incubated Catamaran debuts with $42M to develop CAR NK pipeline

    BIOCENTURY || Catamaran debuted Monday with a $42 million series A round to advance a pipeline of allogeneic CAR NK cell therapies that seed investor SV Health hopes can “democratize access to cell therapy.”

      View Full Article
  • || Startup to use ‘natural killer’ cells on cancer: Catamaran Bio debuts with $42 million from VC investors

    BOSTON GLOBE || Instead of harvesting T cells from the cancer patients being treated, the company wants to obtain natural killer cells — another form of white blood cells — from healthy people. Scientists would use these cells, which have natural cancer-fighting properties, to develop an “off-the-shelf” drug for people diagnosed with malignant tumors.

      View Full Article
  • || Solid Tumors, Meet Off-the-Shelf CAR-NK Cell Therapies. Biotech World, Meet Catamaran Bio.

    BLOG || By Mark Boshar, JD (COO) and Vipin Suri, PhD, MBA (CSO) || Early generations of immune cell therapies blazed new trails as cancer treatments, and their success to date has been in the form of autologous products for treating certain blood cancers. Cell therapies have not yet successfully reached the frontier of combatting solid tumors. Catamaran Bio was founded to pioneer the development of allogeneic cell therapies that can safely and effectively treat solid tumors.

      View Full Article